- Home
- COLL vs KOD Comparison
COLL vs KOD Comparison
Compare COLL & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | KOD |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | COLL | KOD |
|---|---|---|
| Price | $37.27 | $24.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $50.83 | $28.29 |
| AVG Volume (30 Days) | 387.1K | ★ 541.9K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.60 |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.55 | ★ N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $23.23 | $1.92 |
| 52 Week High | $50.79 | $31.18 |
Technical Indicators
Market Signals| Indicator | COLL | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 21.42 | 46.97 |
| Support Level | $34.30 | $23.92 |
| Resistance Level | $39.85 | $26.21 |
| Average True Range (ATR) | 1.61 | 2.02 |
| MACD | -0.83 | -0.02 |
| Stochastic Oscillator | 9.89 | 44.14 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.